Chiome Bioscience Inc. (JP:4583) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Chiome Bioscience Inc. has entered into an exclusive licensing agreement with Asahi Kasei Pharma for the development and commercialization of its anti-CX3CR1 antibody, PFKR. The deal includes an upfront payment of ¥200 million to Chiome and potential milestone payments up to ¥24.8 billion, along with royalties based on future sales.
For further insights into JP:4583 stock, check out TipRanks’ Stock Analysis page.